Innovative vaccines for a healthier world
Interview with CEO Bent Frandsen
Next Event
-
Thu16May202410:00H.C. Andersen Capital Webinar
Presentation of 2024 first quarter results
Join ExpreS2ion CEO Bent Frandsen and CFO Keith Alexander as they provides insights into the 2023 fourth quarter and full-year results. Visit the H.C. Andersen Capital Events website for further details and registration information.
Latest News
Notice to attend the Annual General Meeting in ExpreS2ion Biotech Holding AB (publ)
N.B. This notice has been prepared in both Swedish and English language versions. In the event of any discrepancies between the versions, the Swedish version shall prevail. The shareholders of ExpreS2ion Biotech Holding AB (publ), reg. no. 559033-3729 (the "Company"), are hereby given notice to attend the Annual General Meeting to be held on 5…
Read moreExpreS2ion announces a rights issue of units of approximately SEK 60 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. FOR…
Read moreExpreS2ion to receive approximately SEK 22.5 million dividend payment from AdaptVac ApS
Hørsholm, Denmark, 23 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today announced that it has been notified by the Board of Directors of its associated company, AdaptVac ApS, of the resolution to pay a dividend of DKK 42.5 million (SEK 66.1 million) to its owners. As a result of ExpreS2ion…
Read more